Interesting study about HPV and Pap tests
Oct. 19th, 2007 11:58 amHPV Test More Accurate Than Pap Test at Detecting Cervical
Cancer, NEJM Studies Say
Access this story and related links online:
http://www.kaisernetwork.org/daily_reports/rep_index.cfm?DR_ID=48314
Human papillomavirus tests are more accurate than Pap tests in
the detection of cervical cancer and precancerous changes in the
cervix, according to two studies published on Thursday in the
New England Journal of Medicine, the Wall Street Journal reports
(Tomsho, Wall Street Journal, 10/18). For one of the studies,
Canadian researchers led by Eduardo Franco of McGill University
performed a DNA test that detects HPV and a Pap test on 10,154
women ages 30 to 69. The HPV test detected 95% of cases in which
participants had precancerous changes in the cervix, compared
with 55% for the Pap test, the study found (Emery, Reuters,
10/17). However, the HPV test had a false positive rate of 6%,
compared with 3% for the Pap test, according to the study. The
researchers recommended a shift from the Pap test to the HPV
test as the primary detection method for cervical cancer
(Gellene, Los Angeles Times, 10/18). Franco said that the DNA
test costs about $90, compared with $10 to $20 for the Pap test,
although mass production of the DNA test could help reduce the
cost.
Swedish Study
For the second study, Swedish researchers led by Pontus Naucler
of Lund University performed the tests on 12,527 women in their
30s (Reuters, 10/17). The researchers divided participants into
two groups, one that received both tests and one that received
only the Pap test, and tracked them for an average of four
years. At the start of the study, researchers detected 51% more
cases of cervical cancer or precancerous changes in the cervix
in the group that received both tests, but they detected about
the same number of cases in both groups by the end of the study.
The study did not determine whether the earlier detection with
the HPV test increased life expectancy for participants (Los
Angeles Times, 10/18). FDA has approved only one HPV test, USA
Today reports (Rubin, USA Today, 10/18). Digene's DNA Pap test
-- which combines the traditional Pap test with a DNA test for
13 strains of HPV -- was approved by FDA in as a primary
screening tool for cervical cancer for women ages 30 and older
(Kaiser Daily Women's Health Policy Report, 6/5).
*The Canadian study is available online. The Swedish study also
is available online.
*CBS' "Evening News" on Wednesday included a discussion with CBS
medical correspondent John LaPook about the studies (Couric,
"Evening News," CBS, 10/17). Video of the segment is available
online.
Cancer, NEJM Studies Say
Access this story and related links online:
http://www.kaisernetwork.org/daily_reports/rep_index.cfm?DR_ID=48314
Human papillomavirus tests are more accurate than Pap tests in
the detection of cervical cancer and precancerous changes in the
cervix, according to two studies published on Thursday in the
New England Journal of Medicine, the Wall Street Journal reports
(Tomsho, Wall Street Journal, 10/18). For one of the studies,
Canadian researchers led by Eduardo Franco of McGill University
performed a DNA test that detects HPV and a Pap test on 10,154
women ages 30 to 69. The HPV test detected 95% of cases in which
participants had precancerous changes in the cervix, compared
with 55% for the Pap test, the study found (Emery, Reuters,
10/17). However, the HPV test had a false positive rate of 6%,
compared with 3% for the Pap test, according to the study. The
researchers recommended a shift from the Pap test to the HPV
test as the primary detection method for cervical cancer
(Gellene, Los Angeles Times, 10/18). Franco said that the DNA
test costs about $90, compared with $10 to $20 for the Pap test,
although mass production of the DNA test could help reduce the
cost.
Swedish Study
For the second study, Swedish researchers led by Pontus Naucler
of Lund University performed the tests on 12,527 women in their
30s (Reuters, 10/17). The researchers divided participants into
two groups, one that received both tests and one that received
only the Pap test, and tracked them for an average of four
years. At the start of the study, researchers detected 51% more
cases of cervical cancer or precancerous changes in the cervix
in the group that received both tests, but they detected about
the same number of cases in both groups by the end of the study.
The study did not determine whether the earlier detection with
the HPV test increased life expectancy for participants (Los
Angeles Times, 10/18). FDA has approved only one HPV test, USA
Today reports (Rubin, USA Today, 10/18). Digene's DNA Pap test
-- which combines the traditional Pap test with a DNA test for
13 strains of HPV -- was approved by FDA in as a primary
screening tool for cervical cancer for women ages 30 and older
(Kaiser Daily Women's Health Policy Report, 6/5).
*The Canadian study is available online. The Swedish study also
is available online.
*CBS' "Evening News" on Wednesday included a discussion with CBS
medical correspondent John LaPook about the studies (Couric,
"Evening News," CBS, 10/17). Video of the segment is available
online.